Red Queen Bio raises $36M to build antibodies for viruses AI could create

Red Queen Bio, a biosecurity startup backed by OpenAI, has raised $36 million in total to design antibody drugs against viruses, including ones that AI systems could one day help create, according to The Wall Street Journal. The company is starting with antibodies against bird flu and other influenza viruses and plans its first clinical trials, making it an early mover in a niche that blends drug development with AI safety.

The $36 million total is not huge by biotech standards, where Series A rounds often exceed that figure alone. But the strategic framing is what stands out: Red Queen Bio is explicitly building for a threat landscape that includes pathogens AI could help engineer, not just the natural viruses circulating today. That positions the company at the intersection of two fast-moving fields: computational biology and AI governance.

The name itself is a clue to the strategy. The Red Queen hypothesis, borrowed from evolutionary biology, describes the constant arms race between species, where each must keep adapting just to maintain its position. Applied to infectious disease, it captures the challenge of staying ahead of pathogens that evolve quickly, or in this case, could be designed with new tools. The startup's approach is to use AI to accelerate the design of antibodies, the proteins the immune system uses to neutralize viruses, and turn them into drugs.

OpenAI's backing is a notable signal. The AI lab has publicly wrestled with the dual-use risks of its own technology, including the possibility that large language models could lower the barrier to creating biological weapons. By investing in a company that aims to defend against that scenario, OpenAI is effectively funding one side of the risk equation. The Wall Street Journal reported the total funding, and the involvement of a leading AI lab adds weight to the idea that biosecurity is becoming a mainstream concern for the industry.

The initial focus on influenza makes practical sense. Influenza, including avian flu, has long been a pandemic concern for public health agencies. Antibodies are a promising countermeasure because they can be designed to bind to specific parts of a virus and block infection, but developing them quickly enough to outpace an outbreak is a major challenge. Red Queen Bio's bet is that AI can compress the timeline enough to make antibody drugs viable against fast-moving or novel threats.

The broader market context is favorable. The antibody therapeutics market has grown into a multibillion-dollar industry, though infectious disease remains a smaller slice. The Covid-19 pandemic demonstrated both the potential and the limits of antibody drugs, with several products receiving emergency use authorization before being sidelined by new variants. That history underscores the difficulty of staying ahead of evolving viruses, which is exactly the problem Red Queen Bio is trying to solve with AI-driven design.

Regulatory pathways will be a key test. Any antibody drug Red Queen Bio develops will need to go through clinical trials and approval by agencies like the FDA, a process that typically takes years and carries high failure rates. The company's plan to start with influenza gives it a clearer path, since flu is a well-understood target with established regulatory frameworks. But the harder question is whether regulators and payers will support drugs designed for threats that have not yet emerged.

For founders, investors, and public health leaders, Red Queen Bio is a case study in how AI capital is flowing into biosecurity. It suggests that the next wave of pandemic preparedness may be built not just in government labs, but in startups backed by the same companies developing the AI tools. The $36 million is a down payment on a much larger question: whether humanity can build defenses fast enough to match the speed of AI-enabled threats. The answer will be worked out in clinical trials, boardrooms, and policy debates over the next several years.